Ultima Genomics is a biotechnology company unleashing the power of genomics at scale.
Ultima's mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health.
Ultima Genomics was founded in 2016 by Gilad Almogy. The company is headquartered in Newark, California.
Ultima has developed a fundamentally new sequencing architecture designed to scale beyond conventional approaches, including completely different approaches to flow cell engineering, sequencing chemistry, and machine learning.
Ultima's sequencing machine and software platform, the UG 100, can perform a complete sequencing of a human genome in about 20 hours, with precision comparable to existing options, but does so at a far lower cost per “gigabase,” which is to say per million base pairs of DNA analyzed.
Ultima is currently working with early access partners to put out some early proof of concept studies showing the capabilities of the sequencing technique. The first of these, collaborations with the Broad Institute, Whitehead Institute, the Baylor College of Medicine and more are being presented soon or currently available as preprints.
Ultima Genomics emerged from stealth mode with a $600M in funding on May 31, 2022. Backers included General Atlantic, Andreessen Horowitz, D1 Capital, Khosla Ventures, Lightspeed, Marius Nacht, aMoon, Playground Global, and Founders Fund. The latest round valued the company at over $1B post-money.